Visual Impairment and Blindness - What We Know and What We Have to Know最新文献

筛选
英文 中文
Zebrafish Photoreceptor Degeneration and Regeneration Research to Understand Hereditary Human Blindness 斑马鱼光感受器退化和再生研究以了解遗传性人类失明
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2019-08-20 DOI: 10.5772/INTECHOPEN.88758
M. Iribarne
{"title":"Zebrafish Photoreceptor Degeneration and Regeneration Research to Understand Hereditary Human Blindness","authors":"M. Iribarne","doi":"10.5772/INTECHOPEN.88758","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.88758","url":null,"abstract":"Humans with mutations in photoreceptor-related genes develop forms of retinal degeneration, such as retinitis pigmentosa, cone dystrophy, or Leber congenital amaurosis. Similarly, numerous photoreceptor mutant animal models present phenotypes that resemble retinal degeneration. Zebrafish retina manifests anatomical organization and development remarkably conserved in humans, making these fish a good model to study photoreceptor development and disease. Zebrafish are ideal for forward genetic screens to isolate mutants with visual defects. More recently, CRISPR/Cas system-mediated genome editing has enabled establishment of specific zebrafish photoreceptor mutants. Here, I review zebrafish models of inherited retinal diseases, focusing on rod versus cone photoreceptor mutants. Because zebrafish possess robust regeneration capacity to replace the lost photoreceptors, here I review the current understanding of molecular mechanisms underlying this response. raising the hope of future treatments for this disorder. Here I summarize our current understanding of this regeneration response.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127159264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Diabetic Retinopathy and Blindness: An Epidemiological Overview 糖尿病视网膜病变和失明:流行病学综述
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2019-08-19 DOI: 10.5772/INTECHOPEN.88756
M. Pandova
{"title":"Diabetic Retinopathy and Blindness: An Epidemiological Overview","authors":"M. Pandova","doi":"10.5772/INTECHOPEN.88756","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.88756","url":null,"abstract":"Prevalence of diabetes is rising worldwide. In the course of the last 20 years, blindness and low vision due to diabetic eye complications have increased in large regions in Eastern Europe, North Africa/Middle East, Asia, Latin America, and Oceania. The magnitude and trends of vision-threatening disease are presented. Systemic risk factors for progression to sight-threatening disease are reviewed. The impact of economic and cultural background on early diagnosis and adherence to treatment is highlighted. Current management of diabetic macular edema, proliferative diabetic retinopathy, neovascular glaucoma, and cataract surgery of diabetic patients is outlined, and its contribution to preventing vision loss is reviewed. of blindness from diabetes for men and women between 1948 1962.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"125 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132715211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The Role of Imaging in Age-Related Macular Degeneration 影像在老年性黄斑变性中的作用
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2019-04-30 DOI: 10.5772/INTECHOPEN.82630
A. Victor
{"title":"The Role of Imaging in Age-Related Macular Degeneration","authors":"A. Victor","doi":"10.5772/INTECHOPEN.82630","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.82630","url":null,"abstract":"Age-related macular degeneration (ARMD) is the leading cause of blindness affecting adults. The disease alters the macula, center of the retina, responsible for the keenest vision. Although ARMD is part of the aging process, the exact pathophysiology is still unknown. The evidence suggests that oxidative stress, lipofuscin accumulation, drusen accumulation, chronic inflammation, choroidal neovascularization, and mutations of the complement contribute to the development of ARMD. Early recognition and prompt treatment halt the progression of the disease. The advanced technology in imaging modalities provides comprehensive and complete management at the earliest stage of ARMD. in ARMD without the need of invasive procedure. The utilization of multimodal imaging in diagnosis of ARMD results in early detection and comprehensive management of ARMD.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133787552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Mechanistic Dissection of Macular Degeneration Using the Phosphorylation Interactome 利用磷酸化相互作用组进行黄斑变性的机理解剖
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2019-03-04 DOI: 10.5772/INTECHOPEN.83016
Weilue He, Srinivas Sripathi, Madu Joshua, R. Zhang, Fabunmi Tosin, P. Ambrose, D. Gutsaeva, Wan Jin Jahng
{"title":"Mechanistic Dissection of Macular Degeneration Using the Phosphorylation Interactome","authors":"Weilue He, Srinivas Sripathi, Madu Joshua, R. Zhang, Fabunmi Tosin, P. Ambrose, D. Gutsaeva, Wan Jin Jahng","doi":"10.5772/INTECHOPEN.83016","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.83016","url":null,"abstract":"In the current study, we suggest that phosphorylation reactions of specific proteins in mitochondria and the nucleus are a key step in the progression of age-related macular degeneration (AMD). To determine the molecular mechanism of AMD, we examined proteomic changes under oxidative stress to establish the protein interaction map using in vitro and in vivo models that mimic the complex and progressive characteris-tics of AMD. We postulated that apoptosis can be initiated by phosphorylation reactions under chronic oxidative stress in a region-specific and tissue-specific manner. The analysis of AMD interactome and oxidative biomarker network demonstrated that the presence of tissue- and region-dependent post-translational mechanisms may contribute toward AMD progression through the mitochondrial-nuclear communication. The AMD interactome suggests that new therapeutic targets, including prohibitin, erythropoietin, vitronectin, crystalline, nitric oxide synthase, ubiquitin, and complement inhibition may exist as a proteome network. Further, immunocytochemistry demonstrated that mitochondria could enter the nucleus in the retinal pigment epithelium (RPE) under oxidative stress. The current interactome map implies that a positive correlation may exist between oxidative stress-mediated phosphorylation and AMD progression. The unbiased proteome network provides a basis for understanding oxidative stress-induced mitochondrial dysfunction in AMD and exploring effective therapeutic approaches to treat age-related neurodegeneration. target plate. It was analyzed through matrix-assisted laser/desorption ionization time of flight mass spectrometry (Bruker Ultraflex MALDI-TOF-TOF Mass spectrometer) in a reflector mode. Mass spectra and tandem mass spectra were acquired manually with laser intensity at 2400 and 200 shots per spectrum in MS mode and laser intensity at 3800 and 400 shots in MS/MS mode. The spectra were analyzed using Flex analysis 2.0 and Biotools 2.2 software. Peptide mass was calibrated internally using two trypsin auto digest ions (m/z 842.509, m/z 2211.104). Protein identification was performed using Mascot software to search the National Center for Biotechnology Information database with mouse taxonomy. A missed trypsin cleavage was not allowed and 100 ppm of mass tolerance was applied for the search for the matching peptide. Based on our proteomics data, we tested the following anti-apoptotic or anti-angiogenic molecules: (1) prohibitin (anti-apoptotic mitochondrial-nuclear shuttle); (2) erythropoietin as an anti-apoptotic protein via JAK2/STAT3 pathway; (3) melatonin as an anti-apoptotic and anti-angiogenic molecule protecting cytoskeletal reorganization through PP2A/vimentin pathway; (4) okadaic acid, arginine, and SNAP to control nitric oxide concentration; (5) cardiolipin and cholesterol; (6) anthocyanin (anti-angiogenic via VEGFR2 pathway); (7) phospholipids, fatty acids, cyclodextrin to control lipids and cholesterol concentration.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"48 6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126410953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Biometric Systems and Their Applications 生物识别系统及其应用
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2019-03-01 DOI: 10.5772/INTECHOPEN.84845
Souhail Guennouni, A. Mansouri, A. Ahaitouf
{"title":"Biometric Systems and Their Applications","authors":"Souhail Guennouni, A. Mansouri, A. Ahaitouf","doi":"10.5772/INTECHOPEN.84845","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.84845","url":null,"abstract":"Nowadays, we are talking more and more about insecurity in various sectors as well as the computer techniques to be implemented to counter this trend: access control to computers, e-commerce, banking, etc. There are two traditional ways of identifying an individual. The first method is a knowledge-based method. It is based on the knowledge of an individual’s information such as the PIN code to allow him/her to activate a mobile phone. The second method is based on the possession of token. It can be a piece of identification, a key, a badge, etc. These two methods of identification can be used in a complementary way to obtain increased security like in bank cards. However, they each have their weaknesses. In the first case, the password can be forgotten or guessed by a third party. In the second case, the badge (or ID or key) may be lost or stolen. Biometric features are an alternative solution to the two previous identification modes. The advantage of using the biometric features is that they are all universal, measurable, unique, and permanent. The interest of applications using biometrics can be summed up in two classes: to facilitate the way of life and to avoid fraud.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130586316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Eye Movements during Barking at Print 对着印刷物吠叫时的眼球运动
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2018-11-10 DOI: 10.5772/INTECHOPEN.81898
T. Beelders, A. Stott
{"title":"Eye Movements during Barking at Print","authors":"T. Beelders, A. Stott","doi":"10.5772/INTECHOPEN.81898","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.81898","url":null,"abstract":"In order for educational software coupled with eye-tracking capability to respond with pedagogical appropriateness to a reader’s eye movements, reading metrics must be validly interpreted. These metrics and the types of reading they diagnose, for example, scanning, skimming and reading for meaning, come largely from reading fiction texts in a home language. The use of existing classification systems for disadvantaged South African learners did not yield consistent and credible classification of these learners’ reading. This could be attributed to learners barking at print, that is, decoding the text without comprehending what they were reading beyond the word level. Eye movements of barkers and non-barkers were analysed and no statistically significant differences were found. Barking at print was found to be distinct from mindless reading and mind-wandering, as well as other reading types for both first and second languages. Barking is characterised by slow reading with few regressions, average fixation durations typical of second language reading, and variability in eye-movements between lines of text. This work is significant in that it establishes that eye-movement during barking at print is distinct from other categories of reading. However, further research is needed before valid applications can be made from this work.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"2008 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113966652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration 新生血管性老年性黄斑变性的治疗策略和视觉效果
Visual Impairment and Blindness - What We Know and What We Have to Know Pub Date : 2018-11-05 DOI: 10.5772/INTECHOPEN.81466
Siyang Chaili, S. Adrean
{"title":"Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration","authors":"Siyang Chaili, S. Adrean","doi":"10.5772/INTECHOPEN.81466","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.81466","url":null,"abstract":"The purpose of this chapter is to examine the various treatment strategies used to manage neovascular age-related macular degeneration (nAMD). The chapter will focus on the three main strategies including fixed interval dosing, as needed Pro-Re-Nata (PRN) treatment and Treat-and-Extend (TAE), with its variant the Treat-Extend-Stop (TES) protocol. We will discuss the visual results of randomized clinical trials and retrospective studies using these methodologies and compare their outcomes, the pros and cons of each treatment strategy, as well as the underlying mechanisms that may explain these differences. The results of long-term extension trials following landmark randomized clinical studies and other long-term retrospective studies will also be compared to studies using a fixed interval dosing or the TAE/ TES method. We will also focus on the visual results of the TES protocol and examine recurrence rates, proposing a definition of the recurrence of choroidal neovascularization (CNV) versus increased disease activity. These topics discussed will help optimize anti-VEGF treatment regimens for patients with nAMD over the long term.","PeriodicalId":128554,"journal":{"name":"Visual Impairment and Blindness - What We Know and What We Have to Know","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117278193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书